<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639493</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXR_103</org_study_id>
    <nct_id>NCT03639493</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of CJ-30060 in Healthy Male Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerabillity of CJ-30060 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and
      Exforge® 10/160mg, Crestor® 20mg in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety after a single dose
      administration of CJ-30060 and Exforge® 10/160mg, Crestor® 20mg in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Actual">May 17, 2018</completion_date>
  <primary_completion_date type="Actual">May 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of amlodipine</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of valsartan</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of amlodipine</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of valsartan</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of amlodipine, valsaran, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg
Period 2: receive CJ-30060 10/160/20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: receive CJ-30060 10/160/20mg
Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exforge® tab 10/160mg, Crestor® tab 20mg</intervention_name>
    <description>Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30060 10/160/20mg</intervention_name>
    <description>Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males aged 20 to 45 years at screening

          -  BMI: 18 ~ 29.9kg/m^2

          -  Body weight ≥ 50kg

          -  Subjects who decided to participate in the study and signed informed consent form
             voluntarily after receiving detailed explanation of the study and fully understanding

        Exclusion Criteria:

          -  Subjects who had a medical history of severe cardiovascular, respiratory,
             hepatobiliary, renal, hematological, gastrointestinal, endocrinological,
             immunological, dermatological or neuropsychological disease

          -  Subjects who have symptoms of an acute disease within 28 days before first
             administration

          -  Subjects who have clinically significant active, chronic disease

          -  Subjects who fall under the criteria below in laboratory test

               -  AST/ALT &gt; UNL (upper normal limit) x 2

               -  Total bilirubin &gt; UNL x 1.5

               -  CrCL &lt; 50mL/min

               -  CPK &gt; UNL x 2.5

          -  Subjects with clinically significant low blood pressure at screening test (systolic
             blood pressure is less than 100 mmHg or diastolic blood pressure is less than 60 mmHg)

          -  Subjects with any positive reaction in HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 19, 2018</last_update_submitted>
  <last_update_submitted_qc>August 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

